[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR099078A2 - Un medicamento que comprende acetato de glatiramer - Google Patents

Un medicamento que comprende acetato de glatiramer

Info

Publication number
AR099078A2
AR099078A2 ARP150100073A ARP150100073A AR099078A2 AR 099078 A2 AR099078 A2 AR 099078A2 AR P150100073 A ARP150100073 A AR P150100073A AR P150100073 A ARP150100073 A AR P150100073A AR 099078 A2 AR099078 A2 AR 099078A2
Authority
AR
Argentina
Prior art keywords
glatiramer
acetato
medicinal product
multiple sclerosis
recurrent
Prior art date
Application number
ARP150100073A
Other languages
English (en)
Inventor
Klinger Ety
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43605835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR099078(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of AR099078A2 publication Critical patent/AR099078A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un medicamento que comprende una dosis de 40 mg de acetato de glatiramer, caracterizado porque es para uso en el tratamiento de un paciente que padece esclerosis múltiple recurrente-remitente o que ha experimentado un primer episodio clínico y corre un alto riesgo de desarrollar esclerosis múltiple definida clínicamente, en donde el medicamento ha de administrarse en un régimen de tres inyecciones subcutáneas durante un período de siete días con un intervalo de por lo menos un día entre cada inyección subcutánea.
ARP150100073A 2009-08-20 2015-01-12 Un medicamento que comprende acetato de glatiramer AR099078A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27468709P 2009-08-20 2009-08-20
US33761210P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
AR099078A2 true AR099078A2 (es) 2016-06-29

Family

ID=43605835

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103062A AR077896A1 (es) 2009-08-20 2010-08-20 Terapia de baja frecuencia con acetato de glatiramer. uso. acetato de glatiramer.
ARP150100073A AR099078A2 (es) 2009-08-20 2015-01-12 Un medicamento que comprende acetato de glatiramer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP100103062A AR077896A1 (es) 2009-08-20 2010-08-20 Terapia de baja frecuencia con acetato de glatiramer. uso. acetato de glatiramer.

Country Status (34)

Country Link
US (15) US8399413B2 (es)
EP (5) EP3199172B1 (es)
JP (3) JP6038653B2 (es)
KR (4) KR20140061559A (es)
CN (3) CN105770855A (es)
AR (2) AR077896A1 (es)
AT (1) AT15421U1 (es)
AU (1) AU2010284666B2 (es)
BR (1) BR112012003730A2 (es)
CA (2) CA2876966A1 (es)
CY (2) CY1114537T1 (es)
CZ (2) CZ29723U1 (es)
DE (1) DE202010018377U1 (es)
DK (5) DK3199172T3 (es)
EA (3) EA032283B1 (es)
ES (4) ES2689711T3 (es)
HK (4) HK1165959A1 (es)
HR (4) HRP20130677T1 (es)
HU (2) HUE031282T2 (es)
IL (3) IL218106A0 (es)
LT (3) LT3199172T (es)
ME (2) ME01536B (es)
MX (1) MX2012002082A (es)
NZ (1) NZ598661A (es)
PL (4) PL2405749T3 (es)
PT (4) PT2630962T (es)
RS (2) RS55607B1 (es)
SG (2) SG10201405806SA (es)
SI (4) SI2630962T1 (es)
SK (1) SK501352015U1 (es)
SM (1) SMT201700057B (es)
TW (3) TWI477273B (es)
UA (1) UA103699C2 (es)
WO (1) WO2011022063A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US8077333B2 (en) * 2002-09-09 2011-12-13 Canon Kabushiki Kaisha Printing control apparatus and printing control method
CA2876966A1 (en) 2009-08-20 2011-02-24 Yeda Research And Development Co., Ltd. Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
WO2012051106A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
KR20150111945A (ko) * 2013-01-04 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트 관련 완제의 특성조사
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN103641897B (zh) * 2013-11-27 2017-01-04 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2015195605A1 (en) * 2014-06-17 2015-12-23 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate by oral patches
CN104844697B (zh) * 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107550853B (zh) * 2016-06-30 2020-06-12 深圳翰宇药业股份有限公司 一种醋酸格拉替雷注射液的制备方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US20210283209A1 (en) 2016-08-31 2021-09-16 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
AU2018242998B2 (en) * 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
KR102519053B1 (ko) 2021-02-08 2023-04-06 건국대학교 산학협력단 염산가스의 농도 측정을 위한 수분 전처리 시스템
KR102519054B1 (ko) 2021-03-12 2023-04-06 건국대학교 산학협력단 나피온 드라이어와 수분 전처리장치의 결합시스템
WO2023062511A1 (en) * 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
EP0219899B1 (en) 1985-10-11 1990-08-08 Duphar International Research B.V Automatic injector
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6454746B1 (en) 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
IL140592A0 (en) 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
HU229289B1 (en) 1998-09-25 2013-10-28 Yeda Res & Dev Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
EP1128839A4 (en) 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
NZ517150A (en) 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies
DE60112718T2 (de) 2000-01-20 2006-06-29 Yeda Research And Development Co., Ltd. Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
JP2003522799A (ja) 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス コポリマー１の経口、経鼻および経肺投与製剤
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
JP2003535118A (ja) 2000-06-05 2003-11-25 テバ ファーマシューティカル インダストリーズ リミティド 中枢神経系障害の治療におけるグラチラマーアセテート（共重合体１）の使用
ES2256200T3 (es) 2000-06-07 2006-07-16 Yeda Research And Development Co., Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para neuroproteccion frente a la toxicidad del glutamato.
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
KR100657048B1 (ko) 2001-12-04 2006-12-12 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트의 효능 측정 방법
AU2003283152A1 (en) 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CN100464796C (zh) 2002-11-25 2009-03-04 特克法马许可公司 包括可复位安全释放设备的自动注射器
US7274347B2 (en) 2003-06-27 2007-09-25 Texas Instruments Incorporated Prevention of charge accumulation in micromirror devices through bias inversion
PT1592384E (pt) 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
CA2518079A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
SI1638589T1 (sl) * 2003-05-14 2014-07-31 Teva Pharmaceutical Industries Ltd. Kombinirana terapija z glatiramer acetatom in mitoksantronom za zdravljenje multiple skleroze
NZ546379A (en) 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
US20070244056A1 (en) 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
EP1737297B1 (en) * 2004-03-25 2012-12-19 Janssen Pharmaceutica NV Imidazole compounds
BRPI0510738A (pt) 2004-05-07 2007-11-20 Peptimmune Inc métodos de tratar doenças com copolìmeros aleatórios
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
KR101347105B1 (ko) * 2004-06-25 2014-01-02 더 브리검 앤드 우먼즈 하스피털, 인크. 신경계 장애의 예방을 위한 조성물 및 방법
WO2006029036A2 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
EP1797109B1 (en) 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
PL1799703T3 (pl) 2004-09-09 2010-06-30 Teva Pharma Sposób wytwarzania mieszaniny polipeptydów stosując oczyszczony kwas bromowodorowy
AR052321A1 (es) 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
UA93669C2 (ru) 2005-02-02 2011-03-10 Тева Фармасьютикл Индастриз, Лтд. Способ приготовления полипептидной смеси c использованием гидрогенолиза
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
ES2420404T3 (es) 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
CA2606194A1 (en) 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
US20070059798A1 (en) 2005-09-09 2007-03-15 Alexander Gad Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
KR101440795B1 (ko) 2006-06-30 2014-09-22 애브비 바이오테크놀로지 리미티드 자동 주사 장치
CN101511862A (zh) 2006-07-05 2009-08-19 莫门塔制药股份有限公司 制备共聚物-1的改进方法
CN101883586A (zh) * 2007-10-01 2010-11-10 约翰斯霍普金斯大学 使用环磷酰胺治疗神经性自身免疫疾病
AU2008330093A1 (en) 2007-11-28 2009-06-04 Yeda Research And Development Co., Ltd. Method of delaying the onset of clinically definite multiple sclerosis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
DK2275086T3 (da) 2009-07-15 2012-07-09 Teva Pharma Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
CA2876966A1 (en) 2009-08-20 2011-02-24 Yeda Research And Development Co., Ltd. Low frequency glatiramer acetate therapy
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
WO2012051106A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
KR20150111945A (ko) 2013-01-04 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트 관련 완제의 특성조사
US20160022811A1 (en) 2013-03-12 2016-01-28 Teva Pharmaceutical Industries Ltd. Rituximab induction therapy followed by glatiramer acetate therapy

Also Published As

Publication number Publication date
EA019998B9 (ru) 2016-01-29
TW201521718A (zh) 2015-06-16
SI2630962T1 (sl) 2018-10-30
EP2630962B1 (en) 2018-06-27
CN105770855A (zh) 2016-07-20
PT2630962T (pt) 2018-08-01
LT3199172T (lt) 2018-10-25
EP3409286A1 (en) 2018-12-05
HRP20130677T1 (en) 2013-10-11
IL233468A0 (en) 2014-08-31
EA201691347A3 (ru) 2016-11-30
PL2949335T3 (pl) 2017-07-31
ES2612001T4 (es) 2018-02-07
HK1225310A1 (zh) 2017-09-08
US20150250845A1 (en) 2015-09-10
ES2424692T3 (es) 2013-10-07
SG10201405806SA (en) 2014-11-27
CN107050423A (zh) 2017-08-18
LT2630962T (lt) 2018-10-25
US20150164977A1 (en) 2015-06-18
CY1114537T1 (el) 2016-10-05
KR20140061559A (ko) 2014-05-21
CY1118529T1 (el) 2017-07-12
PT3199172T (pt) 2018-10-18
JP6169644B2 (ja) 2017-07-26
US20120071416A1 (en) 2012-03-22
CA2760802C (en) 2016-01-12
ES2612001T3 (es) 2017-05-11
KR20120090044A (ko) 2012-08-16
US8399413B2 (en) 2013-03-19
EP2405749B1 (en) 2013-05-08
JP2015187125A (ja) 2015-10-29
EA201400394A1 (ru) 2014-10-30
DK2630962T3 (en) 2018-07-23
JP2017132773A (ja) 2017-08-03
SI2405749T1 (sl) 2013-10-30
AT15421U1 (de) 2017-08-15
LT2949335T (lt) 2017-03-27
EA032283B1 (ru) 2019-05-31
HRP20170056T1 (hr) 2017-03-24
EA019998B1 (ru) 2014-07-30
JP6038653B2 (ja) 2016-12-07
US20170196803A1 (en) 2017-07-13
TW201733575A (zh) 2017-10-01
US20180185274A1 (en) 2018-07-05
ES2689711T3 (es) 2018-11-15
EP2405749A4 (en) 2012-08-22
US9402874B2 (en) 2016-08-02
US20150202247A1 (en) 2015-07-23
MX2012002082A (es) 2012-08-23
CA2760802A1 (en) 2011-02-24
DK201600003Y3 (da) 2016-02-12
SG178495A1 (en) 2012-03-29
US20130165387A1 (en) 2013-06-27
EP3409286B1 (en) 2020-08-12
WO2011022063A1 (en) 2011-02-24
IL218106A0 (en) 2012-04-30
JP2013502415A (ja) 2013-01-24
TWI643614B (zh) 2018-12-11
UA103699C2 (ru) 2013-11-11
DK2405749T3 (da) 2013-07-15
EP3199172A1 (en) 2017-08-02
HRP20181254T1 (hr) 2019-01-25
CZ30474U1 (cs) 2017-03-14
EA032287B1 (ru) 2019-05-31
US8969302B2 (en) 2015-03-03
KR20170123354A (ko) 2017-11-07
US20170095523A1 (en) 2017-04-06
US20170296464A1 (en) 2017-10-19
PT2405749E (pt) 2013-07-22
US20160250251A1 (en) 2016-09-01
HK1165959A1 (en) 2012-10-19
CA2876966A1 (en) 2011-02-24
BR112012003730A2 (pt) 2020-07-21
HK1218250A1 (zh) 2017-02-10
EA201691347A2 (ru) 2016-10-31
AU2010284666B2 (en) 2012-12-06
HUE031282T2 (hu) 2017-06-28
US20190054013A1 (en) 2019-02-21
KR20160038057A (ko) 2016-04-06
US20180064639A1 (en) 2018-03-08
SI3199172T1 (sl) 2018-10-30
PL3199172T3 (pl) 2019-01-31
US20110046065A1 (en) 2011-02-24
US20180311149A1 (en) 2018-11-01
US20190175494A1 (en) 2019-06-13
US9155776B2 (en) 2015-10-13
DK2949335T3 (en) 2017-07-31
AU2010284666A1 (en) 2011-09-22
SMT201700057B (it) 2017-03-08
HK1258008A1 (zh) 2019-11-01
DK201600003U1 (da) 2016-01-22
EP3199172A8 (en) 2017-10-11
AR077896A1 (es) 2011-09-28
DE202010018377U1 (de) 2016-02-25
US8232250B2 (en) 2012-07-31
ES2688873T3 (es) 2018-11-07
RS52885B (en) 2014-02-28
EP2405749A1 (en) 2012-01-18
CA2760802F (en) 2011-02-24
PT2949335T (pt) 2017-02-03
TW201119645A (en) 2011-06-16
SK501352015U1 (sk) 2017-07-03
HRP20170056T2 (hr) 2017-12-15
PL2630962T3 (pl) 2018-12-31
EP3199172B1 (en) 2018-07-11
ME02662B (me) 2017-06-20
EP2949335A1 (en) 2015-12-02
TWI477273B (zh) 2015-03-21
HUE039335T2 (hu) 2018-12-28
PL2405749T3 (pl) 2013-12-31
ME01536B (me) 2014-04-20
EA201270292A1 (ru) 2012-12-28
HRP20181253T1 (hr) 2018-11-02
EP2630962A1 (en) 2013-08-28
NZ598661A (en) 2013-02-22
RS55607B1 (sr) 2017-06-30
SI2949335T1 (sl) 2017-05-31
EP2949335B1 (en) 2017-01-04
CZ29723U1 (cs) 2016-08-30
DK3199172T3 (en) 2018-10-08
CN102625657A (zh) 2012-08-01
IL251943A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
JP2015187125A5 (es)
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
AR084816A1 (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CO6361944A2 (es) Combinacion de una insulina y un agonista de glp-1
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
CO2017008395A2 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol
EA201390181A1 (ru) Несущий корпус для лекарственного средства и способ его изготовления
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
UY36537A (es) Método de uso de la respuesta al anticuerpo antiacetato de glatirámero
MY174442A (en) Treating critically ill patients with intravenous ibuprofen
AR122567A2 (es) Terapia de baja frecuencia con acetato de glatiramer
EA201990217A3 (ru) Терапия глатирамером ацетатом с низкой кратностью
MD520Y (en) Method for postoperative treatment of patients with nephrolithiasis
Pasha Various toxicities: 3 case reports
Wu Various toxicities in an elderly patient: case report
Rollstin Increased INR and elevated ALT and AST levels?: case report
TH173838A (th) เครื่องพ่นละอองยาผงแห้ง

Legal Events

Date Code Title Description
FC Refusal